1. Medtech Insight
  2. >>Archive

Excel-Tech buy to add to Natus neurology offering

Natus Medical is set to broaden its neurological portfolio, with the Can$62.5m ($64m) purchase of Excel-Tech, an Oakville, Ontario-based company specialising in developing computer-based diagnostic systems for neurological and sleep disorders. San Carlos, California-based Natus definitively agreed to purchase all outstanding Excel-Tech shares at Can$3.25 per share. Natus said that the deal will confirm its presence as a market leader in neurology and represent a stepping stone to its goal of growing revenue to $250m by the end of 2008. The company believes that the acquisition, expected to close in the first week of December, will be immediately accretive to earnings - Excel-Tech reported revenue of Can$32.5m for the 12 months ending July 31 2007. Excel-Tech will be able to offer its range of EEG patient monitoring systems for epilepsy diagnosis, electromyography systems and intra-operative monitoring systems, to over 80 countries via Natus' distribution routes.

Natus Medical is set to broaden its neurological portfolio, with the Can$62.5m ($64m) purchase of Excel-Tech, an Oakville, Ontario-based company specialising in developing computer-based diagnostic systems for neurological and sleep disorders. San Carlos, California-based Natus definitively agreed to purchase all outstanding Excel-Tech shares at Can$3.25 per share. Natus said that the deal will confirm its presence as a market leader in neurology and represent a stepping stone to its goal of growing revenue to $250m by the end of 2008. The company believes that the acquisition, expected to close in the first week of December, will be immediately accretive to earnings - Excel-Tech reported revenue of Can$32.5m for the 12 months ending July 31 2007. Excel-Tech will be able to offer its range of EEG patient monitoring systems for epilepsy diagnosis, electromyography systems and intra-operative monitoring systems, to over 80 countries via Natus' distribution routes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.